Current Landscape and the New Emerging Therapies in EGFR-positive Non-small Cell Lung Cancer (NSCLC)

Current Landscape and the New Emerging Therapies in EGFR-positive Non-small Cell Lung Cancer (NSCLC) is organized by Antidote Education Company.

Release Date: November 30, 2023
Expiration Date: November 30, 2024

Statement of Purpose:
The overall concept for this educational initiative for community oncologists is to address unmet educational needs and positively impact practice change behaviors by accelerating the dissemination of new information. This initiative will be delivered in a pragmatic format designed to provide relevant and actionable information to the target audience where they are already engaging - on social media platforms. Antidote will work with the faculty and thought leaders to identify and disseminate findings from new studies and recently-published data relevant to Non-small Cell Lung Cancer (NSCLC).

Learning Objectives:
Upon completion of this educational activity, participants will be better able to:

• Be prepared as a member of the community oncology care team to increase the collective knowledge and build confidence with respect to effective management of patients with NSCLC (TKI and Post-TKI progression).
• Equip learners to confidently apply new scientific evidence and accurately communicate options and corresponding expectations to their patients regarding testing and treatment options designed to ensure optimal care.